Product tampering resulted in contents from eight vials of Epogen (epoetin alfa) and Neupogen (filgrastim) 300 mcg being extracted and the vials refilled with a replacement solution, the company said in a Feb. 13 "Dear Healthcare Provider" letter. "Although the replacement solution has thus far been shown to be non-toxic, the sterility of these vials was compromised," therefore posing a safety risk, especially for immune compromised patients, the letter states
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth